General MedicationsORALGeneric
JUXTAPID
LOMITAPIDE MESYLATE
Standard Dose
EQ 40MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary
Approval overview JUXTAPID is listed in Drugs@FDA under application 203858 (NDA).
Review priority: PRIORITY Marketing status: Discontinued Active ingredient LOMITAPIDE MESYLATE Form and strength CAPSULE;ORAL - EQ 40MG BASE Sponsor CHIESI Submission history Latest submission status date: 2026-02-25 00:00:00.
Structured Monograph
Clinical summary
Approval overview JUXTAPID is listed in Drugs@FDA under application 203858 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient LOMITAPIDE MESYLATE Form and strength CAPSULE;ORAL - EQ 40MG BASE Sponsor CHIESI Submission history Latest submission status date: 2026-02-25 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.